Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia

Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia

Azacitidine treatment of myelodysplastic syndromes (MDSs) generally exacerbates thrombocytopenia during the first treatment cycles. A Study of Eltrombopag in Myelodysplastic Syndromes Receiving Azacitidine (SUPPORT), a phase 3, randomized, double-blind, placebo-controlled study, investigated the pla...

תיאור מלא

מידע ביבליוגרפי
Main Authors: Dickinson, M, Cherif, H, Fenaux, P, Mittelman, M, Verma, A, Portella, M, Burgess, P, Ramos, P, Choi, J, Platzbecker, U, Support Study Investigators
פורמט: Conference item
יצא לאור: American Society of Hematology 2018

פריטים דומים

פריטים דומים